Overview

The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
The aim of prospective, open label, single center, randomized controlled trial is to investigate the efficacy of enavogliflozin on exercise performance, diastolic dysfunction, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF).
Phase:
PHASE4
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Sodium-Glucose Transporter 2 Inhibitors